2
4 site of fXa made interactions specific to fXa / ATIII -Glu 37 , Glu 39 , Gln 61 , Ser 173 and Phe
174
(enzyme residues numbered according to equivalent positions in chymotrypsin). Site-directed mutants of these residues in human fXa were generated and tested for their susceptibility to inhibition by ATIII in the presence and absence of H5. The results demonstrate that mutation of one residue, Gln 61 , which forms part of the S1' and S3' pockets 2 , is sufficient to almost completely abolish the H5-induced acceleration of the association rate observed between fXa and ATIII. Thus, in addition to providing a molecular explanation of the acceleration effect, our data provides the first evidence that residues C-terminal to the reactive centre of the serpin are involved in mediating the acceleration of inhibition.
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Experimental Procedures
Materials
The fX activator protein (RVV-X) was isolated from Russell viper venom as described previously (11) . Plasma ATIII was purified from time-expired plasma as described by
Mackay et al. (12) and Nordenman et al. (13) . The Boc-Ile-Glu-Gly-Argamidomethylcoumarin (IEGR-amc), Glu-Gly-Arg-amidomethylcoumarin (EGR-amc) and biotinylated Glu-Gly-Arg-chloromethyl ketone were supplied by Calbiochem-Novabiochem Inc (Melbourne, Vic., Australia). The monoclonal anti-human fXa antibody, methotrexate, avidin-horse radish peroxidase conjugate, horse radish peroxidase substrate and alkaline phosphatase substrate were supplied by Sigma (Sydney, NSW, Australia). The anti-human ATIII antibody was raised against purified ATIII in chickens and purified from the egg yolk as previously described for other proteins (14) . Heparin pentasaccharide was from Sanofi
Recherche (Toulouse, France). The HiTrap™ Q column was from Amersham-Pharmacia (Sydney, NSW, Australia).
Modelling
The structures of human fXa in complex with the inhibitor Rpr208815 (1F0R; 15), ATIII in complex with H5 (1AZX; 6), thrombin in complex with D-Phe-Pro-Argchloromethylketone (1ABJ; 16), trypsin in complex with ecotin (1SLU; 17) and trypsin in complex with Pancreatic Trypsin Inhibitor (2PTC; 18) were obtained from the protein data bank (19, 20) . Modelling was performed using similar methods to those previously described (21, 22) . Specifically, in order to model the P9-P7' of the RCL of ATIII into the active site of fXa, we first superposed the X-ray crystal structures of fXa and the trypsin / ecotin complex using a program by Arthur Lesk (23 and references contained therein). These two structures share 34% sequence identity over the proteinase domain and superpose over 208 Cα atoms by guest on http://www.jbc.org/ Downloaded from 6 with a root mean square (r.m.s.) deviation of 1.02 Å/ATOM. The "mutate" facility within Quanta (Accelrys Inc., San Diego, CA, USA) was used to change the sequence of the P7-P5' of ecotin (SSPVSTMMHCPV) to that of the P7-P5' region of the RCL of ATIII (AVVIAGRSLNPN). The structure of trypsin, all of the mutated ecotin apart from the P7-P5' region and the inhibitor Rpr208815 were then deleted, to leave the structure of fXa with the P7-P5' sequence of ATIII positioned in the active site. The structure of trypsin in complex with Pancreatic Trypsin Inhibitor was superposed onto the model, and this structure was used as a template to correctly position the P1 Arg of ATIII into the S1 subsite of fXa. The edit sequence facility within Quanta was also used to add additional residues (P8T, P9S, P6'R and P7'V) to the P and P' ends of our peptide. The entire model of fXa in complex with the P9-P7'
sequence of the RCL of ATIII was then subjected to CHARMm minimization, first with the proteinase and the backbone atoms of the peptide constrained, then later with no constraints.
Minimization was performed to convergence. A Ramachrandran plot revealed all residues in our modeled RCL peptide were in allowed conformations. Similar methods were used to build the model of thrombin in complex with the P9-P7' region of the RCL of ATIII.
Subsequent to the completion of the modeling and experimental studies described, the Xray crystal structure of the Michaelis serpin-protease complex was determined by Ye et al. (1I99; 24) . We therefore decided to build a complete model of the complex between H5-activated antithrombin and human factor Xa using the structure of serpin 1K in complex with rat trypsin as a template. The structure of H5-activated antithrombin was first superposed onto the serpin 1K molecule in the Michaelis serpin-protease complex using the sequence alignment and superposition facilities available in Quanta (MSI Inc, San Diego). The two structures superposed with an r.m.s. deviation of 1.3 Å over 333 Cα atoms. We then used the structure of serpin 1K as a template to build a model of the RCL of antithrombin using the homology modelling tools available in Quanta. The RCL of antithrombin is one residue 7 longer than that of serpin1K, and hence one residue was inserted with respect to the template after P6'. In order to accommodate this extra residue we performed a local refinement (using CHARMm) upon the region from P4'-P8'. In this way we obtained a model of antithrombin with the loop in a similar conformation to that seen in the X-ray crystal structure of the Michaelis serpin-protease complex.
We superposed the X-ray crystal structure of human factor Xa (pdb identifier 1F0R) onto the structure of rat trypsin portion of the Michaelis serpin-protease complex. between the proteinase and the body of the serpin were observed. The final model was refined (and the two clashes resolved) using CHARMm, first with the backbone residues constrained and later with no constraints.
Mutagenesis, transfection and cell culture
The construction of the expression system for fX using the pNut vector will be described elsewhere 3 . The site-directed mutagenesis of the fX sequence in the pNut vector was accomplished by using the "Quik change mutagenesis kit" (Stratagene) using a PCR-based strategy. Several clones of each mutation in the pNut-fX vector were sequenced and analysed for protein expression.
Baby hamster kidney cells (BHK) were transfected with the wild type and mutant pNutfX vectors. Stable cell lines were selected by the addition of 100 µM methotrexate to Dulbecco's modified Eagle media (DMEM), supplemented with 5 IU/ml penicillin, 5 µg/ml 8 of streptomycin and 10% (v/v) fetal bovine serum. Isolated colonies were screened for fX expression by immunoassay and activity measurements. Serum free medium containing the recombinant fX protein was applied to a nitrocellulose membrane and was probed using the monoclonal anti-human fX antibody (4 µg/ml). Clones that expressed the enzyme were detected by alkaline phosphatase color development. For large scale expression of the recombinant proteins, selected stable cell lines described above were allowed to reach 80% confluence before the media type was changed to a phenol red free Dulbecco's modified
Eagle media (serum-free) which was supplemented with 5 IU/ml penicillin, 5 µg/ml of streptomycin, 100 µM methotrexate, 10 µg/ml of vitamin K1 and 50 µM zinc sulfate. The media from the cells was collected every 48 hrs for 5 collections and was stored at -20°C.
Purification of recombinant Factor X proteins.
Factor X was partially purified from the pooled media using the barium citrate purification method previously described (25) . Briefly, the fX protein was precipitated by the addition of 60 mM barium chloride, followed by the addition 32 mM citrate. The resulting pellet was resuspended in 15 mM sodium citrate and was dialyzed overnight in 10 mM HEPES, 150 mM NaCl, pH 7.4. The solution was clarified by centrifugation at 5,000 x g and loaded onto a Hi-Trap™ Q column. The fX was eluted from the column using a linear gradient from 0.15 M to 1 M NaCl in 10 mM HEPES, pH 7.4 over 50 ml. Sterile glycerol (final concentration of 10% [v/v]) was added, the samples were aliquoted, snap frozen and stored at -70°C. SDS-PAGE was performed by the method of Laemmli (26) . Proteins were visualized by silver staining or transferred to 0.45µm nitrocellulose, probed with a monoclonal anti-human fX antibody (4 µg/ml), and visualized with alkaline phosphatase detection.
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Zymogen activation and enzyme assays
Factor X was activated by incubating with 100 nM RVV-X for 30 min at 37°C in 10 mM HEPES, pH 7.4, 100 mM NaCl, 5 mM CaCl 2 , 0.1% (w/v) PEG 8000 (25) . All enzyme assays described henceforth were also performed in this assay buffer at 37°C.
The concentration of Factor Xa was determined by an active-site specific immunoassay using biotinylated Glu-Gly-Arg-chloromethyl ketone as described previously (27, 28) .
The activity of fXa was routinely measured by determining the rate of hydrolysis of the substrate IEGR-amc using wavelengths of 370 nm and 460 nm for excitation and emission, respectively, over 10 min using a BMG Fluorostar plate reader. For each of the fXa mutants, Second order rate constants for the association between fXa and ATIII were measured using discontinuous assays as described by Olson et al. (29) using plasma-derived ATIII. A fixed concentration of fXa (1 nM) was incubated with 0.01 µM to 1.5 µM ATIII over various time periods. At the end of the incubation, the reaction was quenched by the addition of 10 corresponding ATIII concentration, and linear regression of the plots yielded the slope from which the k ass for the reaction was obtained.
Stoichiometry of inhibition and analysis of the complex formation.
The stoichiometry of inhibition (SI) was determined with a fixed concentration of fXa (10-200 nM) with increasing molar ratios of ATIII to enzyme in the presence and absence of H5. These reactions were allowed to incubate to completion and the residual fXa activity measured, following which residual activity was plotted against the molar ratio of inhibitor to enzyme. Linear regression analysis of the plotted values yields an intercept with the x-axis which in turn equates to the SI. The complexes formed between fXa and ATIII were analysed by separation on a 10% SDS-PAGE and were transferred to 0.45µm nitrocellulose, probed with a chicken anti-human ATIII antibody (7 µg/ml), and visualized by alkaline phosphatase detection.
Results
Modelling:
The hypothesis investigated in this study was that differences in the active site of thrombin and fXa render the latter enzyme more susceptible to inhibition by H5-activated ATIII. Thus, the objective of our modelling studies was to identify putative interactions between the RCL of ATIII and fXa that were absent in the thrombin / RCL model. In order to identify such residues, the two models were superposed and the RCL / active site interactions in each compared. It is important to note that residues that formed interactions with the modeled peptide, but were conserved between the two enzymes, were not targeted for sitedirected mutagenesis. In addition, we did not investigate the position Gln 192 , which has been the subject of extensive investigation by others (30) . In this section, we describe the putative interactions that were identified and the residues in fXa that were targeted for subsequent sitedirected mutagenesis ( Fig. 1 ; Fig. 2A and B). loop is located at the far end of the S1 specificity pocket and comprises a six residue insertion with respect to fXa (see Fig. 1 ). No additional interactions between this region and the modeled peptide in our fXa / RCL model were found when compared to the thrombin / RCL model. The other major insertion, the "60 loop" is replaced by a short α-helix in fXa (see Fig.   2B ). Comparison of the X-ray crystal structures of thrombin and fXa reveals that Lys 60F protrudes into the active site in thrombin, whereas in fXa, Gln 61 occupies an almost equivalent position in 3-dimensional space (see Fig. 2B ). Furthermore, our modelling studies revealed that Gln 61 is able to make a hydrogen bond to both the sidechains of P1'Ser and P3'Asn,
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"bridging" these two residues (Fig. 2B) . We predict that the Lys 60F present in thrombin, even if optimally placed, would only be able to make one such interaction. Using the rotomer libraries available in Quanta, we also investigated whether Gln 61 was capable of making other interactions to those described above. In an alternative conformation, the ε oxygen of the sidechain of Gln 61 could form a hydrogen bond with the backbone nitrogen of the peptide bond between P1' and P2'. However, this interaction would only be predicted to result in one hydrogen bond. Again, the Lys 60F residue present in thrombin would be unable to form such an interaction. These data suggest that Gln 61 represents a major difference in the active site of fXa as compared to thrombin. We predicted that this residue may confer an enhanced ability to interact with the RCL of ATIII and in order to test this prediction we generated the mutant, fXa Q61A
.
Our model revealed a putative salt bridge between Glu 37 of fXa and the P6' Arg ( Fig. 2A) .
A two residue insertion in thrombin maps to this region and comparison of the structures reveal that no equivalent residue to Glu 37 exists in thrombin. Furthermore, we noted that Glu 39 of fXa, whilst not directly interacting with residues in the RCL of ATIII in our model, was only 6Å from the P4'-P5' peptide bond nitrogen with which it could potentially interact. We therefore decided to test, via site-directed mutagenesis, whether either Glu 37 or Glu 39 affected the interaction between fXa and H5-activated ATIII.
The S-side specificity pockets of both fXa and thrombin have been extensively characterised using both biochemical and structural studies. In our model, the P1-P3 residues made numerous contacts with the active site of fXa and thrombin that were conserved between both enzymes. In addition, the specificity of the S2 pocket of both thrombin and fXa has been characterized in some detail (31) (32) (33) specificity.
Finally, we observed that the sidechain of Ser 173 formed a hydrogen bond with the sidechain of P8 Thr of the ATIII RCL ( Fig. 2A) . Again, this putative interaction was absent in thrombin, Ser 173 being substituted by an Arg in this enzyme (Fig. 1) . In order to test whether this residue was important for the interaction between fXa and ATIII, the fXa 
Characterisation of mutant and wild type recombinant fXa
The mutant fXa molecules were successfully expressed along with the wild type molecule in the expression system, yielding 1.6 mg/l of purified fX. The fX molecules were activated to fXa using purified Russell's viper venom as described previously (25 representing P4-P1 residues made us concerned that these mutations had caused changes to the fXa active site distant from the site of the actual mutations. Glu 37 and Glu 39 would be anticipated to interact directly only with substrate residues C-terminal to the cleavage sites, most likely P5' and P6'. Thus the fact that these mutations had changed interactions at P4-P1 sites led us to conclude that the mutations had caused larger scale changes to the active site of fXa than intended. We therefore also mutated these Glu residues to Gln residues. The mutants produced by this more conservative mutagenesis strategy had K m values for IEGRamc which were still decreased in much the same way as the Ala residue mutants, fXa E37Q had a normal k cat value and fXa E39Q had a decreased k cat value.
Stoichiometry of interaction between factor Xa molecules and antithrombin
We investigated whether any of the mutant fXa molecules were altered in their interaction with ATIII with respect to the SI. In the absence of H5, all serpins displayed SI values of close to 1 for the interaction between serpin and enzyme. In the presence of H5, the SI of the wild type enzyme interacting with ATIII increased to 1.4 as has been found by others (3). , which was 1.7-fold increased in terms of the acceleration achieved.
However, the most effective mutation made was the Q61A substitution. The increase in k ass induced by H5 activation of ATIII was only 4.5 fold for this mutant, which indicates that a very important additional interaction mediated by this residue with the RCL of H5-activated ATIII was all but abolished.
Discussion
The structural basis underlying the well characterized allosterically-mediated increase in interaction between H5-activated ATIII and fXa has proved somewhat elusive. The crystal structures of ATIII alone and in complex with the H5 have been solved (38, 39, 6) Here we have modeled the interaction between the RCL of ATIII and fXa and compared these data to a thrombin / RCL model. In particular, we aimed to identify residues in the active site of fXa that made specific interactions not present in the thrombin / RCL model.
We reasoned that such interactions might mediate the unique acceleration in interaction seen between H5-activated ATIII and fXa, which is not observed with thrombin. Using this approach, we were able to identify a number of putative interactions that were unique to the model of fXa in complex with the RCL of ATIII. Our predictions were tested by mutating the active site residues of fXa to alanine residues to abolish such interactions. Support for a putative interaction would be provided by the mutant enzyme no longer displaying a marked increase in the second order rate constant for association with ATIII upon H5 activation. This should also be further supported by evidence that the mutation has not caused a widespread change to the active site of the protease which may lead to "false positives", where the increase in the association rate constant is no longer seen for structural reasons, rather than the loss of a specific interaction. This was tested by carefully examining the interaction of the enzyme with peptide substrates. Our expectation at the outset of the studies was that the increase in association would be mediated by a number of interactions, which would have a cumulative effect.
Our data reveal that much of the increase in association appeared to be mediated by a localised interaction, namely that between the Gln 61 residue of fXa and the RCL of ATIII.
Thus fXa Q61A had a 22-fold lower increase in k ass for the interaction with ATIII in the presence of H5. While the SI for inhibition of the mutant by ATIII was normal in the absence of H5, it showed no increase in the presence of H5 as seen for wild type enzyme. An increase in the SI for the interaction between ATIII and fXa in the presence of H5 has been noted previously by other investigators (3) and was postulated to be related to the extra interactions mediated by H5 activation retarding insertion of the RCL into the A-sheet of the serpin. This would then shift the balance between the inhibitory and substrate pathways of the serpin slightly towards the substrate pathway and thus yield the increase in SI. The lack of an increase in SI for the fXa Q61A mutant might therefore be attributed to the abolition of the major extra interaction mediated by H5 activation and thus this meshes well with the lack of acceleration in the association rate constant seen with this mutant. The mutant enzyme appeared to be normal in other respects, as judged by a normal affinity of interaction with the IEGR-amc substrate, ruling out possible contribution by gross structural changes to the active site. Analysis of the X-ray crystal structure of fXa, and our modelling data, revealed that Gln 61 forms part of the S1' and S3' subsites. In particular, we predict that this residue is capable of forming hydrogen bonds to the sidechains of P1' Ser and P3' Asn, or alternatively forming a hydrogen bond to the backbone nitrogen atom of the peptide bond between P1' and P2'. These data strongly indicate that allosteric activation of ATIII by H5 has the major effect of bringing the P' region of the RCL of antithrombin into contact with the Gln 61 residue in the active site of the enzyme.
Less dramatic changes were observed for the other mutants of fXa. The fXa S173A and fXa F174A mutants were close to normal in terms of the acceleration mediated by H5 binding.
The fXa F174A mutant did have decreased affinity for the IEGR-amc substrate, but this was most likely due to the loss of the specific interaction with the P4 Ile residue, as demonstrated by the normal affinity of the enzyme for the EGR-amc substrate. The mutants at the Glu 37 and Glu 39 were more complicated to analyse, since substitution of an alanine or glutamine residue at these positions appeared to mediate an increase in the affinity of these enzymes for the IEGR-amc substrate and mixed effects on the rate of hydrolysis. This finding was unexpected, since these residues are on the opposite side of the active site to the subsites that interact with the P4-P1 positions of a substrate. Thus, the small decrease or increases in acceleration of association mediated by the H5 for these mutants should be viewed with caution, since it might be reflective of changes to the active site architecture, rather than affecting a specific interaction. Overall, the data for mutants at these positions suggest that there might be some interactions being mediated by these residues in the active site of fXa, but these appear limited compared to the interactions being mediated by Gln 61 , where a 22-fold effect was observed, compared to 1-3-fold effects for the Glu 37 and Glu 39 mutants.
However, these data lend support to our hypothesis that the P' region of antithrombin is at least in part responsible for mediating the enhanced interaction seen between fXa and H5-activated ATIII.
The results from this study were not only surprising in terms of the localization of the change in interaction between fXa and ATIII activated by H5, they are also somewhat contradictory to previous studies on this topic. Theunissen et al. (43) showed that substitutions at the P1' and P3' positions of the RCL of ATIII markedly decreased the interaction of ATIII with thrombin in the presence of heparin, but had only moderate effects on fXa interactions with ATIII in the presence of heparin. A more recent study by Chuang et al. (44) found that the RCL residues P6-P3' of ATIII did not contribute substantially to the increase in association seen with H5-activated ATIII and fXa, although it must be noted that no substitutions were made at P1' position. Rezaie (45) Recent studies of the interaction between H5-activated antithrombin and fXa (44) have suggested the possibility that an exosite on antithrombin is exposed upon binding H5 and that it is the exosite which provides the additional interaction mediating the acceleration of the interaction mediated by H5. The X-ray crystal structure of the Michaelis complex between serpin1K and rat trypsin (24) revealed that the majority of serpin/proteinase interactions occur between the RCL of the serpin and the proteinase. From our modeling studies we predict a similar paucity of extra-RCL interactions in the complex between fXa and antithrombin.
Analysis of the model of the Michaelis complex between antithrombin and factor Xa reveal that the nearest non-RCL sidechain atom is over 8 Å away, suggesting that it is unlikely that Gln 61 itself is acting as an exosite. Thus we suggest that the simplest explanation of our data is that Gln 61 plays an crucial role in mediating the interaction with H5-activated antithrombin by forming hydrogen bonds with the P' region of the RCL. However, we cannot exclude the possibility that an antithrombin specific exosite on factor Xa does exist -for example the complex between factor Xa and antithrombin may adopt a strikingly different conformation to that seen in the complex between trypsin and serpin 1K. Alternatively, an exosite may come into play after initial docking during the conformational change to the final complexed state.
Heparin pentasaccharide has just progressed successfully through phase II clinical trials for use as an antithrombotic compound, thus understanding the mechanism of action of this compound would seem to be vital in this context and also in furthering our knowledge of this complex system. The H5 is thus far thought to act mostly through its ability to mediate the increased association of ATIII with fXa. In light of this, the illustration here of potential interactions underlying the mechanism of action whereby H5-activated ATIII has a strongly The sequence alignment between factor Xa and thrombin is based upon a structural comparison of the two enzymes performed using a program by Lesk (23) . Thrombin contains several insertions with respect to factor Xa that are not structurally equivalent -these amino acids are contained in parenthesis in the sequence of factor Xa. Identical residues are shaded pink. Amino acids that differ between the two enzymes are shaded in green, or cyan if they were mutated in this study. The "60-loop" and "149-loop" are underlined and labeled. The conventional numbering scheme for factor Xa is based upon chymotrypsin numbering and is shown above the sequences. Insertions with respect to chymotrypsin are marked "-1" and deletions "+1". and P3' residues are labeled. Shown in red is the "60 loop" of factor Xa, with Gln 61 in red stick. The two predicted hydrogen bonds to the sidechain of P1' and P3' are represented by black dashed lines. We predict that Gln 61 may be able to form an alternative conformation which is shown in magenta. In this conformation we predict that Gln 61 is able to form a hydrogen bond to the backbone N of P1' (represented by the blue dashed line). The "60-loop" of thrombin is shown in grey in the position that it occupies when thrombin and factor Xa are superposed. The 60F lysine residue can be seen snaking into the active site, occupying a similar position to the sidechain Gln 61 in factor Xa. The figure was prepared using Molscript (48) . All values shown had standard errors of less than 10%.
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